Loading clinical trials...
Loading clinical trials...
This was a non-interventional (observational), retrospective, cohort study of women with hormone receptor (HR)-positive and human epidermal growth factor receptor-type 2 (HER2)-negative advanced breas...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Novartis
NCT06257264 · Breast Cancer, Small Cell Lung Cancer, and more
NCT05735080 · Breast Cancer, Breast Cancer Metastatic, and more
NCT06348134 · Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, HER2-positive Breast Cancer, and more
NCT06388122 · HER2-negative Breast Cancer, Hormone-receptor-positive Breast Cancer, and more
NCT07222215 · Estrogen-receptor-positive Breast Cancer, Metastatic Breast Cancer, and more
Novartis Pharmaceuticals
East Hanover, New Jersey
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions